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To the Editor: We appreciate the 
opportunity to respond to the letter by 
Markert et al., “CYP2C9 Polymorphism 
Is Not a Major Determinant of 
Bosentan Exposure in Healthy 
Volunteers.”1 In response to our study 
on genetic predictors of bosentan-
induced liver injury in pulmonary 
arterial hypertension (PAH) patients, in 
which we demonstrated an association 
between the CYP2C9*2 allele, encoding 
the cytochrome P450 complex subunit 
2C9, and liver injury,2 Markert et al. 
report steady-state bosentan pharma-
cokinetics in 36 healthy volunteers. 
They show that plasma bosentan 
levels were highly variable and not 
associated with CYP2C9 metabolizer 
phenotype. Consistent with a role for 
CYP2C9 in the formation of the major 
active metabolite hydroxy bosentan 
 (RO48-5033), levels of RO48-5033 were 
68.7% greater in extensive metabolizers 
than in poor metabolizers.
The pharmacokinetic data obtained 
by Markert et al. suggest that the genetic 
association that we reported is not eas-
ily explained by differences in bosen-
tan plasma concentrations between 
CYP2C9 genotype groups. As Markert 
et al. point out, CYP2C9-dependent 
intrahepatic bosentan concentrations 
may be more relevant and may not be 
directly related to bosentan plasma 
concentrations. Although hepatic 
transporter polymorphisms were not 
associated with bosentan hepatotoxicity 
in our study,2 the possibility exists that 
transporter function is altered in PAH 
patients as a result of disease or drug 
treatment. Furthermore, as discussed 
in our paper, there is a possibility that 
CYP2C9*2 is not a causative single-
nucleotide polymorphism (SNP) but 
tags a regulatory SNP.2 The difference 
in study populations may also have 
influenced the reported results. The 
pharmacokinetic study by Markert et al. 
was carried out in healthy volunteers, 
whereas our genetic association study 
was performed in PAH patients receiv-
ing steady-state bosentan for clinical 
indications. As also noted by Markert 
et al., differences in pharmacokinet-
ics between CYP2C9 metabolizer 
groups might be more apparent in PAH 
patients, especially because they may 
have a longer duration of exposure. 
Indeed, previously published bosentan 
pharmacokinetic data for PAH patients 
show that bosentan exposure is not pro-
portional to dose and is approximately 
twofold higher than that in healthy sub-
jects.3 In addition, because PAH affects 
expression of endothelin receptors,4 it 
may affect the tissue-to-plasma ratios 
of bosentan in these patients. Finally, 
the possibility that concurrent medica-
tions in PAH patients affect bosentan 
 pharmacological and toxicological 
properties cannot be excluded.
Although studies in healthy volunteers 
provide important information about 
human pharmacokinetic characteristics, 
it is difficult to extrapolate this informa-
tion to toxicity phenotypes in relevant 
and complex patient populations. We 
welcome further investigations to eluci-
date mechanisms of liver injury and the 
potential role of pharmacogenomics in 
patient groups that are candidates for 
bosentan therapy.
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